Abstract
P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization. Multiple lines of evidence suggest that the level of on-treatment platelet reactivity inhibition with P2Y12 ADP receptor antagonists correlates with thrombotic recurrences. Recent studies observed a relationship between excessive platelet reactivity inhibition and bleedings. Together these data support the potential of platelet reactivity measurement to prevent thrombotic events without increasing bleeding. In the present review we aimed to summarize evidences of a therapeutic window for P2Y12-ADP receptor antagonists and the potential of platelet reactivity monitoring and individualized antiplatelet therapy to optimize the clinical outcome in patients suffering from an acute coronary syndrome or undergoing percutaneous coronary intervention.
Keywords: Percutaneous coronary intervention, stent, thrombosis, platelet, P2Y12-ADP receptor, pharmacogenomics, VASP
Current Pharmaceutical Design
Title:Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?
Volume: 18 Issue: 33
Author(s): Marc Laine, Laurence Camoin-Jau, Jacques Bessereau, Armero Sebastien, Franck Paganelli and Laurent Bonello
Affiliation:
Keywords: Percutaneous coronary intervention, stent, thrombosis, platelet, P2Y12-ADP receptor, pharmacogenomics, VASP
Abstract: P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization. Multiple lines of evidence suggest that the level of on-treatment platelet reactivity inhibition with P2Y12 ADP receptor antagonists correlates with thrombotic recurrences. Recent studies observed a relationship between excessive platelet reactivity inhibition and bleedings. Together these data support the potential of platelet reactivity measurement to prevent thrombotic events without increasing bleeding. In the present review we aimed to summarize evidences of a therapeutic window for P2Y12-ADP receptor antagonists and the potential of platelet reactivity monitoring and individualized antiplatelet therapy to optimize the clinical outcome in patients suffering from an acute coronary syndrome or undergoing percutaneous coronary intervention.
Export Options
About this article
Cite this article as:
Laine Marc, Camoin-Jau Laurence, Bessereau Jacques, Sebastien Armero, Paganelli Franck and Bonello Laurent, Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?, Current Pharmaceutical Design 2012; 18 (33) . https://dx.doi.org/10.2174/138161212803251934
DOI https://dx.doi.org/10.2174/138161212803251934 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early Pathogenesis of Atherosclerosis: The Childhood Obesity
Current Pharmaceutical Design Transition of Care for Patients with Diabetes
Current Diabetes Reviews The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design The Influence of Practising Physical Activity on the Prevention and Treatment of Gestational Diabetes: A Systematic Review
Current Diabetes Reviews Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance
Current Diabetes Reviews Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Antioxidant and Antinociceptive Activities of Methanol Extract of Muehlenbeckia sagittifolia
Current Traditional Medicine Psychotropics and Methadone in Acquired Long QT Syndrome
Current Psychopharmacology Quantification of Specific Glycation Sites in Human Serum Albumin as Prospective Type 2 Diabetes Mellitus Biomarkers
Protein & Peptide Letters Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Editorial (Thematic Issue: Metabolic Syndrome in Pregnancy)
Current Pharmaceutical Biotechnology Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Cardiac Complications in Hypertension and Diabetes: Role of Sympathetic Nervous Activity
Current Hypertension Reviews BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients
Recent Patents on Anti-Cancer Drug Discovery